文献速递血液净化与透析

透析合并COVID-19患者的康复情况:ERACODA研究中诊断后3个月的健康结局

Recovery of dialysis patients with COVID-19: health outcomes 3 months after diagnosis in ERACODA.
PubMed 文献 · Nephrol Dial Transplant · 2022-01-01

基于欧洲肾脏协会COVID-19数据库(ERACODA)纳入2020年2月1日至2021年3月31日诊断COVID-19的2449例血液透析患者,评估诊断后3个月生存、居住及功能与心理健康状态。3个月生存率在未住院、住院非ICU和ICU患者分别为90%、73%和40%,存活者中87%功能状态和94%心理状态恢复至病前水平。

要点

  • 3个月生存率:未住院患者90%,住院非ICU患者73%,ICU患者40%。
  • 存活者中87%功能状态、94%心理状态恢复至病前水平。
  • 高龄、就诊时衰弱评分高及ICU入住与更差功能结局相关。

核心结论

  • COVID-19诊断后28天至3个月期间死亡率低,多数存活者在诊断后3个月恢复至病前功能和心理健康水平。

研究设计与样本

  • 分析欧洲肾脏协会COVID-19数据库(ERACODA)中2020年2月1日至2021年3月31日诊断COVID-19的透析患者数据。
  • 纳入2449例血液透析患者(平均±标准差年龄67.5±14.4岁,62%男性),854例存活患者有完整随访数据。
  • 采用逻辑回归分析与社会康复相关的患者特征。

主要发现

  • 3个月生存概率:未住院患者(n=1087)为90%,住院但未入ICU患者(n=1165)为73%,入ICU患者(n=197)为40%。
  • COVID-19诊断后28天至3个月患者生存率几乎无下降。
  • 3个月时87%患者功能状态恢复至病前水平,94%心理状态恢复至病前水平。
  • 仅少数存活者仍住院(0.8%-6.3%)或住在养老院(约5%)。
  • 较高年龄、就诊时较高衰弱评分及ICU入住与更差功能结局相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coronavirus disease 2019 (COVID-19)-related short-term mortality is high in dialysis patients, but longer-term outcomes are largely unknown. We therefore assessed patient recovery in a large cohort of dialysis patients 3 months after their COVID-19 diagnosis. METHODS: We analyzed data on dialysis patients diagnosed with COVID-19 from 1 February 2020 to 31 March 2021 from the European Renal Association COVID-19 Database (ERACODA). The outcomes studied were patient survival, residence and functional and mental health status (estimated by their treating physician) 3 months after COVID-19 diagnosis. Complete follow-up data were available for 854 surviving patients. Patient characteristics associated with recovery were analyzed using logistic regression. RESULTS: In 2449 hemodialysis patients (mean ± SD age 67.5 ± 14.4 years, 62% male), survival probabilities at 3 months after COVID-19 diagnosis were 90% for nonhospitalized patients (n = 1087), 73% for patients admitted to the hospital but not to an intensive care unit (ICU) (n = 1165) and 40% for those admitted to an ICU (n = 197). Patient survival hardly decreased between 28 days and 3 months after COVID-19 diagnosis. At 3 months, 87% functioned at their pre-existent functional and 94% at their pre-existent mental level. Only few of the surviving patients were still admitted to the hospital (0.8-6.3%) or a nursing home (∼5%). A higher age and frailty score at presentation and ICU admission were associated with worse functional outcome. CONCLUSIONS: Mortality between 28 days and 3 months after COVID-19 diagnosis was low and the majority of patients who survived COVID-19 recovered to their pre-existent functional and mental health level at 3 months after diagnosis.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Hemmelder MH, Noordzij M, Vart P, et al. Recovery of dialysis patients with COVID-19: health outcomes 3 months after diagnosis in ERACODA. Nephrol Dial Transplant. 2022. PMID: 35030246. doi:10.1093/ndt/gfac008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。